A 84441
Latest Information Update: 24 Jan 2013
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Class Antibacterials; Quinolones
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Feb 2001 Profile reviewed but no significant changes made
- 22 Oct 1997 No-Development-Reported for Cancer in USA (Unknown route)
- 19 May 1995 New profile